PDS Biotechnology Corporation (SWB:EU6) Financings
Financings
| Raise | Date |
|---|---|
| Warrant exercise of common stock warrants (common stock or pre-funded warrants) Closed: US$3.9M raised · US$0.22 a share Buyers: NantWorks (exercised warrants to purchase an aggregate of 17,699,115 shares (or pre-funded warrants in lieu thereof)) Use of proceeds: Advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, PDS0101 partnership strategy and general corporate purposes | Nov 10, 2026 |
| Private placement of units of common stock or pre-funded warrants with common warrants Tranche closed: US$11.3M raised · US$0.2825 a unit · a Common Warrant to purchase one-half of one Private Placement Share Buyers: Nant Capital, LLC (Led the round; obligated to purchase $10,000,000 at the Milestone Closing); AB Group Ltd. (Obligated to purchase $1,000,000 at the Milestone Closing) Use of proceeds: Repay outstanding indebtedness, working capital and general corporate purposes, including clinical development, R&D and G&A expenses | Sep 14, 2026 |
| Registered direct offering of shares of common stock (or pre-funded warrants) and accompanying warrants Announced: about US$5.3M · US$0.91 a share · Warrants at US$1 for 60 months · Craig-Hallum Dealers: Craig-Hallum (lead) Use of proceeds: Continuation of the VERSATILE-003 Phase 3 trial, other research and development and general corporate purposes | Nov 11, 2025 |
| Registered direct offering of shares of common stock (or common stock equivalents) and warrants Announced: about US$11M · US$1.5 a share · Warrants at US$1.5 for 60 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Insiders: Certain directors of the Company participate at a combined purchase price of $1.66 Use of proceeds: Research and development expenses and general corporate purposes | Feb 27, 2025 |